
Dr. Dvorin’s research focuses on the molecular pathogenesis of the human malaria parasite Plasmodium falciparum. The major goal of the Dvorin lab is to identify fundamental biological processes within the parasite life cycle. One of these fundamental processes is the regulated and efficient egress from human erythrocytes that occurs during asexual replication. The parasite relies on egress for a sequential round of invasion; this allows exponential expansion of the parasite during the blood-stage of malaria. Parasite egress requires a calcium-mediated signal, but the proteins that mediate the critical calcium-dependent steps of parasite egress have not been fully identified or characterized. Using genetic, cell biological, and novel molecular biology techniques, the Dvorin lab is interested in multiple aspects of parasite egress from an infected human erythrocyte.
Dr. Jeffrey Dvorin received his undergraduate degree in Physics from Brown University. He then attended the University of Pennsylvania School of Medicine to pursue a combined M.D./Ph.D. in the Medical Scientist Training Program. During his graduate work, he studied the mechanisms of nuclear entry for the human immunodeficiency virus in the laboratory of Michael Malim. He completed his pediatric residency at the Children’s Hospital of Philadelphia and then moved to the Children’s Hospital Boston for his fellowship in Pediatric Infectious Diseases. After finishing his clinical fellowship year in June 2007, he joined the laboratory of Dr. Manoj Duraisingh in the Department of Immunology and Infectious Diseases at the Harvard School of Public Health to study the molecular pathogenesis of the human malaria parasite Plasmodium falciparum. His research focused on developing novel genetic techniques to understand P. falciparum growth and replication with the ultimate goal of identifying new therapies for malaria. In Dr. Duraisingh’s laboratory, Dr. Dvorin identified an essential kinase for P. falciparum replication PfCDPK5 that is potentially an ideal target for rational design of anti-malarial medications.
* Co-first authors